Brownium? Researchpost 235
Brownium: 10x new research on populism, bank lending, emission targets, ESG anarchy, climate overlay, green audit washing, ESG compensation, brown fear of missing out (FOMO), and shades of green
Green signaling: Researchpost 234
8x new research on digital SDG support, sustainable compliance, shareholder engagement, divestments, sustainable illiteracy, sustainable theory, and sustainable finance in general
Clever green investors: Researchpost 232
13x new research on green kids, green poor, attractive purpose, biodiversity data, biodiversity flows, ESG rating cost, green audits, sustainable women, effective engagement, DEI losses, DACH impact market, and the Yale asset allocation
Postgrowth: Researchpost 231
10x new research on fossil fuel finance, coal insurance, postgrowth literature, financial nature risks, social ratings, ESG herding, resilient ESG, ESG regulation, divestment and transition deficits
Finfluence: Researchpost 230
Finfluence: 5x new research on flexible sustainability beliefs, sectoral ESG, brown Tech companies, fund outperformance myths, and positive finfluence
ESG-Exit: Researchpost 229
ESG-Exit: 12xnew research on carbon pricing, brown loans, brown default risk, climate M&A challenges, greenwashing, stranded real estate, impact investing potential, worker-CEO pay gap, carbon border taxes and volatility as a risk measure
Brown bank securities: Researchpost 228
7x new research on deadly climate change, green political power, brown bank securities, ESG rating diversion, ESG factor performance and equity drawdowns
SDG-Kennzahlen: Nur eine gut?
SDG-Kennzahlen: Hier werden Nachhaltigkeits-Rangfolgen von Wertpapier-Indizes mit sechs Nachhaltigkeitskennzahlen gebildet, davon fünf SDG-Kennzahlen. Die Rangfolgen unterscheiden sich teilweise stark. Eine SDG-Kennzahl wird als besonders attraktiv eingeschätzt.
Nature risks: Researchpost 227
Nature risks: 11x new research on green volatility, climate alliances, brown asset managers, green accounts, omnibus, nature risks, green turbulence, exclusions, stakeholders, medtech, venture risks